[
  {
    "ts": null,
    "headline": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns",
    "summary": "Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock a strong long-term opportunity.",
    "url": "https://finnhub.io/api/news?id=dd95196df08df83dcb835a89e877361f36e0ec6beb9048b6078e84cf1c31a0ac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752622845,
      "headline": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns",
      "id": 135959071,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401241138/image_1401241138.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock a strong long-term opportunity.",
      "url": "https://finnhub.io/api/news?id=dd95196df08df83dcb835a89e877361f36e0ec6beb9048b6078e84cf1c31a0ac"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.",
    "summary": "A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.",
    "url": "https://finnhub.io/api/news?id=0e15745a1e0fd582fee87595a2b2f4b9b2bb03e91fee78d263adfce61f5e54b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752601800,
      "headline": "Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.",
      "id": 135964850,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.",
      "url": "https://finnhub.io/api/news?id=0e15745a1e0fd582fee87595a2b2f4b9b2bb03e91fee78d263adfce61f5e54b6"
    }
  },
  {
    "ts": null,
    "headline": "Health Canada extends Evkeeza approval for children with HoFH",
    "summary": "The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.",
    "url": "https://finnhub.io/api/news?id=2e1ccdc30fb44e418bd2da71c603c8910c9eaa278e8e9d287eeb2d5f6520ed8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752572768,
      "headline": "Health Canada extends Evkeeza approval for children with HoFH",
      "id": 135941632,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.",
      "url": "https://finnhub.io/api/news?id=2e1ccdc30fb44e418bd2da71c603c8910c9eaa278e8e9d287eeb2d5f6520ed8b"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Value Equity Fund Q2 2025 Commentary",
    "summary": "Parnassus Value Equity Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=8da32aa99f91d77430a6333e00c9076e612b9dbc7e69491bd5ddc74be3c14dc2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752569820,
      "headline": "Parnassus Value Equity Fund Q2 2025 Commentary",
      "id": 135943720,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8da32aa99f91d77430a6333e00c9076e612b9dbc7e69491bd5ddc74be3c14dc2"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock on Our Buy List and 2 to Brush Off",
    "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 8.4%. This drop is a stark contrast from the S&P 500’s 5.4% gain.",
    "url": "https://finnhub.io/api/news?id=ee30cdd7b85593f37ffb4624181ac52703049a3ed37f26c5b7c48c0e40434097",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752554404,
      "headline": "1 Healthcare Stock on Our Buy List and 2 to Brush Off",
      "id": 135965920,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 8.4%. This drop is a stark contrast from the S&P 500’s 5.4% gain.",
      "url": "https://finnhub.io/api/news?id=ee30cdd7b85593f37ffb4624181ac52703049a3ed37f26c5b7c48c0e40434097"
    }
  }
]